Why do clinicians managing T2D patients need to be aware of the trials, physiologic basis, side effects and other dimensions of fixed ratio, long-acting insulin-GLP-1 RA combination regimens?

Why do clinicians managing T2D patients need to be aware of the trials, physiologic basis, side effects and other dimensions of fixed ratio, long-acting insulin-GLP-1 RA combination regimens?

Why do clinicians managing patients with T2D need to be aware of the trials, physiologic basis, side effects and other dimensions of deploying fixed ratio, long-acting insulin-GLP-1 RA combination regimens?


Created by

CMEducation Resources IQ&A Interactive Intelligence Zone

Presenter

Vivian Fonseca, MD

Vivian Fonseca, MD

Professor of Medicine and Pharmacology
Tullis Tulane Alumni Chair in Diabetes
Chief, Section of Endocrinology
Tulane University Health Sciences Center
Past President, Science and Medicine
American Diabetes Association